Contraceptive choices for women with inflammatory bowel disease

Journal of Family Planning and Reproductive Health Care

Volumn 29, Issue 3, 2003, Pages 127-135

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

COPPER INTRAUTERINE DEVICE; GESTAGEN; MEDROXYPROGESTERONE ACETATE; MESALAZINE; ORAL CONTRACEPTIVE AGENT;

BODY MASS; BONE MINERAL; CONTRACEPTION; CROHN DISEASE; DISEASE ASSOCIATION; ENTERITIS; FEMALE; FERTILITY; GASTROENTEROLOGY; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; PRACTICE GUIDELINE; PREGNANCY; REPRODUCTION; REVIEW; TREATMENT PLANNING; ULCERATIVE COLITIS;

EID: 0037699429     PISSN: 14711893     EISSN: None     Source Type: Journal    
DOI: 10.1783/147118903101197782     Document Type: Review

References (76)

1. British Society of Gastroenterology. Inflammatory bowel disease. London: British Society of Gastroenterology, 2003.
2. Kane SV, Sable K, Hanauer SB. The menstrual cycle and its effect on inflammatory bowel disease and irritable bowel syndrome: a prevalence study. Am J Gastroenterol 1998; 93: 1867-1872.
3. Friedman S, Regueiro MD. Pregnancy and nursing in inflammatory bowel disease. Gastroenterol Clin North Am 2002; 31: 265-273.
4. Alstead EM. Inflammatory bowel disease in pregnancy (Review). Postgrad Med J 2002; 78: 23-26.
5. Lamah M, Scott HJ. Inflammatory bowel disease and pregnancy. Int J Colorectal Dis 2002; 17: 216-222.
6. Katz JA, Pore G. Inflammatory bowel disease and pregnancy. Inflamm Bowel Dis 2001; 7: 146-157.
7. Rubin SD, Korelitz BI. Considerations regarding fertility and pregnancy in the management of inflammatory bowel disease. Pract Gastroenterol 1996; 20: 12-23.
8. Moody GA, Probert C, Jayanthi V, et al. The effects of chronic ill health and treatment with sulphasalazine on fertility amongst men and women with inflammatory bowel disease in Leicestershire. Int J Colorectal Dis 1997; 12: 220-224.
9. Baird DD, Narendranathan M, Sandler RS. Increased risk of preterm birth for women with inflammatory bowel disease. Gastroenterology 1990; 99: 987-994.
10. Mayberry JF, Weterman IT. European survey of fertility and pregnancy in women with Crohn's disease: a case control study by European collaborative group. Gut 1986; 27: 821-825.
11. Hudson M, Flett G, Sinclair TS, et al. Fertility and pregnancy in inflammatory bowel disease. Int J Gynaecol Obstet 1997; 58: 229-237.
12. Scott EM, Gaywood I, Scott BB for the British Society of Gastroenterology. Guidelines for osteoporosis in coeliac disease and inflammatory bowel disease. London: British Society of Gastroenterology, 2000.
13. Janssen NM, Genta MS. The effects of immunosuppressive and antiinflammatory medications on fertility, pregnancy, and lactation. Arch Intern Med 2000; 160: 610-619.
14. Diav-Citrin O, Park Y-H, Veerasuntharam G, et al. The safety of mesalamine in human pregnancy: a prospective controlled cohort study. Gastroenterology 1998; 114: 23-28.
15. Alstead EM, Ritchie JK, Lennard-Jones JE, et al. Safety of azathioprine in pregnancy in inflammatory bowel disease. Gastroenterology 1990; 99: 443-446.
16. Rutgeerts P. A critical assessment of new therapies in inflammatory bowel disease. J Gastroenterol Hepatol 2002; 17: S176-S185.
17. Su C, Salzberg BA, Lewis JD, et al. Efficacy of anti-tumour necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol 2002; 97: 2577-2584.
18. Lichtenstein GR, Bala M, Han C, et al. Infliximab improves quality of life in patients with Crohn's disease. Inflamm Bowel Dis 2002; 8: 237-243.
19. British National Formulary, No. 44, September 2003. London: British Medical Association and the Royal Pharmaceutical Society of Great Britain, 2003. www.BNF.org
20. Fraser AG, Orchard TR, Robinson EM, et al. Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. Aliment Pharmacol Ther 2002; 16: 1225-1232.
21. Morgan SL, Baggott JE, Lee JY, et al. Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during long-term, low dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention. J Rheumatol 1998; 25: 441-446.
22. Weaver K, Glasier A. Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill. Contraception 1999; 59: 71-78.
23. Elliman, A. Interactions with hormonal contraception. J Fam Plann Reprod Health Care 2000; 26: 109-111.
24. Csemiczky G, Alvendal C, Landgren BM. Risk for ovulation in women taking a low-dose oral contraceptive (Microgynon) when receiving antibacterial treatment with fluoroquinolone (ofloxacin). Adv Contracept 1996; 12: 101-109.
25. Maggioli F, Puricelli G, Dottorini M, et al. The effect of ciprofloxacin on oral contraceptive steroid treatments. Drugs Exp Clin Res 1991; 17: 451-454.
26. Faculty of Family Planning and Reproductive Health Care. Clinical Effectiveness Unit first prescription of combined oral contraception: recommendations for clinical practice. J Fam Plann Reprod Health Care 2000; 26: 27-38.
27. Reimold AM. New indications for treatment of chronic inflammation by TNF-alpha blockade. Am J Med Sci 2003; 325: 75-92.
28. Thomas KJ, Nicholl JP, Coleman P. Use and expenditure on complementary medicine in England: a population based study. Complement Ther Med 2001; 9: 2-11.
29. Langmead L, Chitnis M, Rampton DS. Use of complementary therapies by patients with IBD may indicate psychosocial distress. Inflamm Bowel Dis 2002; 8: 174-179.
30. Chief Medical Officer (CMO). Important interactions between St John's Wort (Hypericum perforatum) preparations and prescribed medication (4). London: Department of Health, 2000.
31. Dresser GK, Shwarz UI, Wilkinson GR, et al. Coordinate induction of both cytochrome P4503A and MDR1 by St John's Wort in healthy subjects. Clin Pharmacol Ther 2003; 73: 41-50.
32. Sands BE. Decreased fertility after restorative proctocolectomy. Inflamm Bowel Dis 2002; 8: 307-308.
33. Why mothers die 1997-1999. The confidential enquiries into maternal deaths in the United Kingdom, 5, 1-365. London: Royal College of Obstetricians and Gynaecologists Press, 2001.
34. Mogadam DM, Korelitz BI, Ahmed SW, et al. The course of inflammatory bowel disease during pregnancy and postpartum. Am J Gastroenterol 1981; 75: 265-269.
35. Grimmer SFM, Back DJ, Orme ML'E, et al. The bioavailability of ethinyloestradiol and levonorgestrel in patients with an ileostomy. Contraception 1986; 33: 51-59.
36. World Health Organization (WHO). Selected practice recommendations for contraceptive use. Geneva: WHO, 2002.
37. World Health Organization (WHO). Improving access to quality care in family planning. Medical eligibility criteria for contraceptive use (2nd edn). Geneva: WHO, 2000.
38. Thromboembolic Risk Factors (THRIFT) Consensus Group. Risk of and prophylaxis for venous thromboembolism in hospital patients. BMJ 1992; 305: 567-574.
39. Scottish Intercollegiate Guidelines Network Secretariat. Prophylaxis of venous thromboembolism, 62, 1-47. 2003.
40. Guedon C, Le Cam-Duchez V, Lalaude O, et al. Prothrombotic inherited abnormalities other than factor V Leiden mutation do not play a role in venous thrombosis in inflammatory bowel disease. Am J Gastroenterol 2001; 96: 1448-1454.
41. Novacek G, Miehsler W, Kapiotis S, et al. Thromboembolism and resistance to activated protein C in patients with inflammatory bowel disease. Am J Gastroenterol 1999; 94: 685-690.
42. van Milligen de Wit AW, van Deventer SJ, Tytgat GN Immunogenic aspects of primary sclerosing cholangitis: implications for therapeutic strategies. Am J Gastroenterol 1995; 90: 893-900.
43. Vessey MP, Doll R, Fairbairn AS, et al. Postoperative thromboembolism and the use of oral contraceptives. BMJ 1970; 3: 123-126.
44. World Health Organization (WHO). Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combine injectable contraceptives. Results of an international, multicentre, case control study. Contraception 1998; 57: 315-324.
45. Vandenbroucke JP, Koster T, Briet E, et al. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-1457.
46. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, et al. Enhancement by factor V Leiden mutation of risk of deep venous thrombosis associated with oral contraceptives containing a third generation progestogen. Lancet 1995; 346: 1593-1596.
47. Spitzer WO, Heinemann LAJ, Lewis MA, et al. Third generation oral contraceptives and the risk of venous thrombo-embolic disorders: an international case-control study. BMJ 1996; 312: 83-68.
48. Jick H, Jick SS, Gwewich K, et al. Risk of idiopathic cardiovascular death and non-fatal venous thromboembolism in women using oral contraceptives with differing progestogen components. Lancet 1995; 346: 1589-1593.
49. DeCherney A. Bone-sparing properties of oral contraceptives. Am J Obstet Gynecol 1996; 174: 15-20.
50. Berenson AB, Radecki CM, Grady JJ, et al. A prospective controlled study of the effects of hormonal contraception on bone mineral density. Obstet Gynecol 2001; 98: 576-582.
51. Wanichsetakul P, Kamudhamas A, Watanaruangkovit P, et al. Bone mineral density at various anatomic bone sites in women receiving combined oral contraceptives and depot-medroxyprogesterone acetate for contraception. Contraception 2002; 65: 407-410.
52. Banks E, Berrington A, Casabonne D. Overview of the relationship between use of progestogen-only contraceptives and bone mineral density. Br J Obstet Gynaecol 2001; 108: 1214-1221.
53. Gbolade BA. Depo-Provera and bone density. J Fam Plann Reprod Health Care 2002; 28: 7-11.
54. Scholes D, Lacroix AZ, Ichikawa LE, et al. Injectable hormone contraception and bone density: results from a prospective study. Epidemiology 2002; 13: 581-587.
55. Habtezion A, Silverberg MS, Parkes R, et al. Risk factors for low bone density in Crohn's disease. Inflamm Bowel Dis 2002; 8: 87-92.
56. Bernstein CN, Blanchard JF, Leslie W, et al. The incidence of fracture among patients with inflammatory bowel disease. Ann Intern Med 2000; 133: 795-799.
57. Pardthiasong T. Return of fertility after use of the injectable contraceptive Depo-Provera - an updated data analysis. J Biosoc Sci 1984; 16: 23-24.
58. Farley TNM, Rosenberg MJ, Rowe PJ, et al. Intrauterine contraceptive devices and pelvic inflammatory disease: an international perspective. Lancet 1992; 339: 785-788.
59. Jamieson DJ, Hillis SD, Duerr A, et al. Complications of interval laparoscopic tubal sterilization: findings from the United States collaborative review of sterilization. Obstet Gynecol 2000; 96: 997-1002.
60. Royal College of Obstetricians and Gynaecologists (RCOG). Male and female sterilisation (National Evidence-based Clinical Guidelines), No. 4. London: RCOG Press, 1999.
61. Kerin JF, Carignan CS, Cher D. The safety and effectiveness of a new hysteroscopic method for permanent birth control: results of the first Essure pbc clinical study. Aust N Z J Obstet Gynaecol 2001; 41: 364-370.
62. Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit. Emergency contraception. J Fam Plann Reproductive Health Care 2003; 29(2): 9-16.
63. Peppercorn MA. Definition of and risk factors for inflammatory bowel disease. http://www.uptodate.com
64. Cosnes J, Carbonnel F, Carrat F, et al. Oral contraceptive use and the clinical course of Crohn's disease: a prospective cohort study. Gut 1999; 48: 218-222.
65. Lashner BA, Kane SV, Hanauer SB. Lack of association between oral contraceptive use and ulcerative colitis. Gastroenterology 1990; 99: 1032-1036.
66. Lashner BA, Kane SV, Hanauer SB. Lack of association between oral contraceptive use and Crohn's disease: a community-based matched case-control study. Gastroenterology 1989; 97: 1442-1447.
67. Kurina LM, Goldacre MJ, Yeates D, et al. Depression and anxiety in people with inflammatory bowel disease. J Epidemiol Community Health 2001; 55: 716-720.
68. Collins JF. Stress and gut inflammation: the perception becomes reality. Inflamm Bowel Dis 2001; 7: 80-81.
69. Metcalf AM, Dozois RR, Kelly KA. Sexual function in women after proctocolectomy. Ann Surg 1986; 204: 624-627.
70. Trachter AB, Rogers AI, Leiblum SR. Inflammatory bowel disease in women: impact on relationship and sexual health. Inflamm Bowel Dis 2002; 8: 413-421.
71. Nightingale AJ, Middleton W, Middelton SJ, et al. Evaluation of the effectiveness of a specialist nurse in the management of inflammatory bowel disease (IBD). Eur J Gastroenterol Hepatol 2000; 12: 967-973.
72. Hilsden RJ, Scott CM, Verhoef MJ. Complementary medicine use by patients with inflammatory bowel disease (see Comments). Am J Gastroenterol 1998; 93: 697-701.
73. Cable M. The role of patients' organizations. Int Disabil Stud 1988; 10: 181-182.
74. Mayberry JF. Information booklets for patients with inflammatory bowel disease. Int Disabil Stud 1988; 10: 179-180.
75. Maunder RG, de Rooy EC, Toner BB, et al. Health-related concerns of people who receive psychological support for inflammatory bowel disease. Can J Gastroenterol 1997; 11: 681-685.
76. Godber D, Mayberry JF. A preliminary report on the role of lay counselling amongst patients with inflammatory bowel disease. J Roy Soc Med 1988; 81: 528-529.